Shanghai Shen Lian Biomedical Corp

SHG:688098 China Biotechnology
Market Cap
$504.26 Million
CN¥3.70 Billion CNY
Market Cap Rank
#13256 Global
#3377 in China
Share Price
CN¥9.01
Change (1 day)
+0.00%
52-Week Range
CN¥5.10 - CN¥15.40
All Time High
CN¥35.61
About

Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.

Shanghai Shen Lian Biomedical Corp - Asset Resilience Ratio

Latest as of September 2025: 3.87%

Shanghai Shen Lian Biomedical Corp (688098) has an Asset Resilience Ratio of 3.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
CN¥60.40 Million
Cash + Short-term Investments
Total Assets
CN¥1.56 Billion
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Shanghai Shen Lian Biomedical Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Shen Lian Biomedical Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥60.40 Million 3.87%
Total Liquid Assets CN¥60.40 Million 3.87%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Shen Lian Biomedical Corp maintains only 3.87% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Shen Lian Biomedical Corp Industry Peers by Asset Resilience Ratio

Compare Shanghai Shen Lian Biomedical Corp's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Shanghai Shen Lian Biomedical Corp (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Shanghai Shen Lian Biomedical Corp.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.82% CN¥43.81 Million CN¥1.55 Billion -7.37pp
2023-12-31 10.19% CN¥162.38 Million CN¥1.59 Billion -8.82pp
2022-12-31 19.01% CN¥305.12 Million CN¥1.61 Billion -7.52pp
2021-12-31 26.53% CN¥424.08 Million CN¥1.60 Billion -4.67pp
2020-12-31 31.20% CN¥472.45 Million CN¥1.51 Billion --
pp = percentage points